<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02441283</url>
  </required_header>
  <id_info>
    <org_study_id>M13-576</org_study_id>
    <secondary_id>2015-000452-24</secondary_id>
    <nct_id>NCT02441283</nct_id>
  </id_info>
  <brief_title>A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530</brief_title>
  <official_title>A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a rollover study to assess resistance and durability of response to ABT-493 and/or
      ABT-530 in subjects who have participated in Phase 2 or 3 clinical studies with these agents
      for the treatment of chronic HCV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 22, 2015</start_date>
  <completion_date type="Actual">October 15, 2019</completion_date>
  <primary_completion_date type="Actual">October 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing persistence of resistance-associated amino acid variants</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>It will be assessed by population, deep, and/or clonal nucleotide sequencing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who maintain a sustained virologic response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of medical events related to the progression of liver disease</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Summarize medical events related to progression of liver disease including events of hepatic decompensation, change in Child-Pugh classification, liver transplantation, hepatocellular carcinoma, and/or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant IP-10 results</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>IP-10 is used to assess liver fibrosis in participants with chronic liver disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Aspartate transaminase to platelet ratio index (APRI)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The aspartate transaminase to platelet ratio index (APRI) is used to assess liver fibrosis in participants with chronic liver disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant FibroScan and/or liver biopsy results, if available</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The FibroScan and/or liver biopsy are used to assess liver fibrosis in participants with chronic liver disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant FibroTest Score</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>A biomarker test that used blood serum to generate a score that correlates to the degree of liver damage in participants</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">384</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>All subjects enrolled in the study</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow up study that includes sample collection (diagnostic intervention) procedures only and no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-530</intervention_name>
    <description>Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.</description>
    <arm_group_label>All subjects enrolled in the study</arm_group_label>
    <other_name>Pibrentasvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493</intervention_name>
    <description>Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.</description>
    <arm_group_label>All subjects enrolled in the study</arm_group_label>
    <other_name>Glecaprevir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is male or female 18 years of age or older

          2. The subject has received at least one dose of an ABT-493- and/or ABT 530 containing
             regimen in a prior AbbVie HCV Phase 2 or 3 study

          3. The interval between the last dose of the AbbVie DAA therapy from the previous
             clinical study and enrollment in Study M13-576 must be no longer than 2 years for
             subjects who have not been retreated. Subject who have been treated with a
             commercially available anti-HCV treatment may be enrolled greater than 2 years after
             the last dose of the AbbVie DAA therapy from the previous clinical study.

          4. The subject must voluntarily sign and date the informed consent form approved by an
             Independent Review Board or Ethics Committee prior to the initiation of any
             study-specific procedures.

          5. Subject completed the post-treatment period of an eligible prior study.

        Exclusion Criteria:

          1. The investigator considers the subject unsuitable for the study for any reasons (e.g.,
             failure to comply with study procedures in the prior AbbVie clinical study).

          2. Receipt of any investigational HCV antiviral treatment after receiving ABT-493 and/or
             ABT-530 in the prior study.

          3. Subjects who experienced non-virologic treatment failure due to premature
             discontinuation of study drug in prior study of ABT-493/ABT-530.

          4. Participation in AbbVie's Study M15-942 protocol for re-treatment for virologic
             failure in the prior Phase 2 or 3 study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Health Specialists of the Southeast /ID# 136725</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Felizarta /ID# 141033</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Res. Ctr. /ID# 141799</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118-1408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research &amp; Education, Inc. /ID# 169591</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite San Diego /ID# 141040</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite San Diego /ID# 141047</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite San Diego /ID# 141048</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research /ID# 169477</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners /ID# 141028</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Ctr. LLC /ID# 141024</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105-6800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 141039</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Binghamton Gastroenterology /ID# 141026</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Center for Liver Dis /ID# 155390</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677-3471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Gastroenterology Cli /ID# 141036</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One /ID# 169478</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research, PLLC /ID# 141042</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TX Clinical Research Institute /ID# 141037</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inquest Clinical Research /ID# 141045</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521-2415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TX Liver Inst, Americ Res Corp /ID# 136727</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Mary's Hospita /ID# 165106</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital, Darlinghurst /ID# 155395</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincents Hospital /ID# 155394</name>
      <address>
        <city>East Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital /ID# 155392</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital /ID# 155396</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 155391</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital /ID# 155393</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc /ID# 155397</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St. Pierre /ID# 155399</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven /ID# 155398</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary /ID# 155400</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre /ID# 155401</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Frankfurt /ID# 169817</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mauss, Schmutz, Hegener, Athma /ID# 155402</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologisch-Hepatologi /ID# 169820</name>
      <address>
        <city>Kiel</city>
        <zip>24146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital /ID# 155403</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro-Hepato &amp; Geriatric Ctr /ID# 141060</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinical Investigations Group /ID# 141059</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Care P.S.C. /ID# 141061</name>
      <address>
        <city>San Juan</city>
        <zip>00959</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital /ID# 155405</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS /ID# 155406</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital /ID# 155404</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital /ID# 155407</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>American Samoa</country>
  </removed_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Sustained virologic response</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Direct Acting Antiviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

